BetterLife Pharma Secures CAD $2M Insider-Backed Convertible Debenture to Fund BETR-001 IND
BETRF has more than doubled off its 52-week low of $0.028 on elevated volume (2.0× avg).
Summary
BetterLife Pharma closed a CAD $2 million convertible debenture financing from an insider, providing crucial capital to advance its lead drug candidate, BETR-001, towards clinical trials and address its going concern warning.
Key Events · Financing and Capital Events · BETRF
-
CAD $2 Million Convertible Debenture Closed
The company closed a CAD $2,000,000 convertible debenture financing on June 22, 2026, with a 10% interest rate and maturity on June 1, 2027. The principal is convertible at CAD $0.06 per unit, with each unit comprising one common share and one warrant exercisable at CAD $0.10. A director and insider subscribed for the entire amount, providing essential capital for IND-enabling activities for BETR-001 and general working capital.
-
Warrant Expiry Dates Extended
BetterLife Pharma extended the expiry dates of over 14 million outstanding share purchase warrants by one year, including 2,041,644 warrants held by directors and an officer.
-
Executive Compensation and Grants
Executive Chairman Doug Drysdale was granted 3,500,000 stock options at an exercise price of $0.065, and other officers received 3,250,000 stock options at $0.07. Additionally, 100,000 common shares were issued for corporate advisory services.
-
Strategic Partnership for BETR-001 Development
The company engaged Syner-G BioPharma Group to oversee GMP manufacturing of BETR-001, its lead non-hallucinogenic LSD-derivative candidate, as it progresses towards an Investigational New Drug (IND) filing and Phase 1 trials in Q1 2027.
Analysis · BETRF · Life Sciences
This filing confirms the closing of a CAD $2 million convertible debenture financing, entirely subscribed by a director and insider. This capital infusion is critical for BetterLife Pharma, especially following its recent 20-F filing which raised substantial doubt about its ability to continue as a going concern. While the conversion terms are dilutive at CAD $0.06 per unit, securing this funding is a lifeline for the company to advance its lead candidate, BETR-001, towards an Investigational New Drug (IND) filing and Phase 1 trials. The full insider participation signals strong commitment to the company's survival and pipeline progress.
At the time of this filing, BETRF was trading at $0.08 on OTC in the Life Sciences sector, with a market capitalization of approximately $12.3M. The 52-week trading range was $0.03 to $0.09. This filing was assessed with neutral market sentiment and an importance score of 9 out of 10.